Bagsværd, Denmark and South San Francisco, Ca, Us, 9 December 2025 Novo Nordisk and Akero Therapeutics Inc. Akero Nasdaq AKRO today announced that Novo Nordisk s acquisition of Akero, announced on 9 October 2025, has bee
Akero Therapeutics, Inc. (AKRO) — Live Session & Technical Brief
Updated Nov 21, 2026 5:01 AM ET · Prev Close $54.48
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (+0.32%) in Pharmaceuticals & Therapeutics
Akero Therapeutics, Inc. (AKRO) is trading within a tight intraday band at $54.65 (+0.32%, 11.60x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, AKRO is outperforming the S&P 500 by +3.96%. 14-day RSI stands at 67.3, keeping momentum in a bullish regime.
Bagsværd, Denmark and South San Francisco, Ca, Us, 9 December 2025 Novo Nordisk and Akero Therapeutics Inc. Akero Nasdaq AKRO today announced that Novo Nordisk s acquisition of Akero, announced on 9 October 2025, has bee
Price ($54.65) holds above both 20-day ($54.36) and 50-day ($52.91) moving averages.
Market & Sector Relative Strength
AKRO outperforming the S&P 500 by +3.96%Recent AKRO Catalyst Headlines
Verified WireLiver fibrosis is a growing global concern, driven by chronic conditions like hepatitis, obesity, and alcohol use. This progressive liver disease, marked by scar tissue buildup, can advance to cirrhosis or liver cancer i
Akero Therapeutics AKRO is catching the market s eye after shares moved slightly higher this week, following a recent stretch of strong year-to-date gains. Investors are now keeping an eye on what might come next for the
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b Symmetry trial and indicate potential to reduce risk of disease progression in compensated cirrhosis F4c
1–3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $54.36 (20-day SMA support) for directional breakout confirmation.
Technical Regime (AKRO)
BULLISH MA TRENDRetail & Crowd Sentiment
NeutralTraders on StockTwits express bullish sentiment towards SAIH, anticipating a potential multi-day price surge as momentum picks up.
About Akero Therapeutics, Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address …
Get Instant AKRO Catalyst Alerts
Receive an email alert when AKRO triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversAKRO Session & Catalyst FAQ
Why is AKRO stock trading near flat today?
Akero Therapeutics, Inc. (AKRO) is trading within a tight intraday band at $54.65 (+0.32%, 11.60x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, AKRO is outperforming the S&P 500 by +3.96%. 14-day RSI stands at 67.3, keeping momentum in a bullish regime.
Is AKRO stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 11.60x relative volume (high participation). Our multi-factor model currently rates AKRO as BUY. Review full valuation, quality, and timing signals on the AKRO Buy or Sell Decision Brief →
What is AKRO's intrinsic value and expected trading range?
At $54.65, AKRO's modeled 1-to-3 session range is $53.43 – $55.87, with a key inflection level at $54.36 (20-day SMA support). Compare current price against multi-year cash flow projections in the AKRO Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for AKRO?
RSI at 67.3 reflects constructive bullish momentum. AKRO trades at $54.65 relative to its 20-day SMA ($54.36) and 50-day SMA ($52.91), reflecting a bullish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.